ArticleJournal of experimental orthopaedics2025
A randomised controlled trial confirms the non-superiority of bone marrow aspirate (BMA) from the posterior iliac crest and proximal tibia compared to platelet rich plasma (PRP) in the treatment of knee osteoarthritis.
Article in Journal of experimental orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal stromal cells therapy for remodeling the joint microenvironment: mechanisms, nanotechnology-enhanced strategies, and translation prospects.Stem cell research & therapy · 2026Review
- A randomised controlled trial confirms the non-superiority of bone marrow aspirate (BMA) from the posterior iliac crest and proximal tibia compared to platelet rich plasma (PRP) in the treatment of knee osteoarthritis.Journal of experimental orthopaedics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The reported clinical trial aimed to determine the clinical efficacy of ex vivo mesenchymal stromal cells (MSCs) derived from bone marrow (BM), aspirated from the posterior iliac crest and proximal tibia, in comparison to autologous platelet-rich plasma (PRP) for the knee osteoarthritis (KOA) treatment and to assess the differences in cellular yield between the two harvest sites. Methods: A single-centre, parallel, randomised controlled trial was designed to investigate the clinical effects of bone marrow aspirate (BMA) from the posterior iliac crest compared to BMA from the proximal tibia in treating KOA, with a control group receiving PRP. Ninety patients with KOA were divided equally among the three groups. Visual Analogue Score (VAS) and Western Ontario and McMaster Universities Arthritis Index (WOMAC) score were used for clinical outcome evaluation at 6 months after the treatment, and cellular analysis of BMA was performed. Results: Cell count confirmed that the posterior iliac crest was significantly more densely populated with mononuclear cells than the proximal tibia. Flow cytometric analysis of ex vivo BMA also confirmed a significantly greater number of MSCs in the BM-derived from the posterior iliac crest when compared with the proximal tibia, together with a significantly higher number of platelets. The analysis confirmed that the improvement in early pain and function scores after each treatment was statistically significant within each of the three groups (median VAS decrease: PRP Group -2 ( Conclusion: The iliac crest yields a higher concentration of MSCs compared to the proximal tibia. However, both sources demonstrated a beneficial clinical outcome in the treatment of KOA, with no evidence of superiority over PRP treatment. Level of Evidence: Level I.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.